VTGN

Vistagen Therapeutics Inc

0.1707

Oct 29 • 3:59 PM ET +0.0007 (0.41%)

0.1707

Aftermarket • 6:02 PM ET 0.0000 (0.00%)

Healthcare Biotechnology USA Nano NASD

Peers: DFTX SPTX RLMD ANRO TNXP VNDA AZR HELP MNOV CING

| Held by: VTI VXF

Scroll to Statements

Index	-
Market Cap	7.57M
Enterprise Value	-23.38M
Income	-67.62M
Sales	2.50M
Book/sh	0.55
Cash/sh	0.72
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	41
IPO	Jun 21, 2011

P/E	-
Forward P/E	-
PEG	-
P/S	3.03
P/B	0.31
P/C	0.24
P/FCF	-
EV/EBITDA	-
EV/Sales	-9.35
Quick Ratio	3.07
Current Ratio	3.07
Debt/Eq	0.03
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-1.70
EPS next Y	-1.54
EPS next Q	-0.38
EPS this Y	19.40%
EPS next Y	-4.41%
EPS next 5Y	3.20%
EPS past 3/5Y	40.10% 34.11%
Sales past 3/5Y	- 3.10%
EPS Y/Y TTM	-7.55%
Sales Y/Y TTM	-
EPS Q/Q	35.86%
Sales Q/Q	504.92%
Earnings	Aug 14 BMO
EPS/Sales Surpr.	17.81% 195.20%

Insider Own	0.42%
Insider Trans	0.00%
Inst Own	26.94%
Inst Trans	-11.76%
ROA	-129.22%
ROE	-166.46%
ROIC	-275.51%
Gross Margin	69.58%
Oper. Margin	-2784.33%
Profit Margin	-2702.64%
SMA20	-19.38%
SMA50	-28.64%
SMA200	-61.88%
Trades

Shs Outstand	44.38M
Shs Float	44.19M
Short Float	5.60%
Short Ratio	0.20
Short Interest	2.47M
52W High	5.14 -96.68%
52W Low	0.17 3.20%
Volatility	7.15% 7.50%
ATR (14)	0.02
RSI (14)	30.12
Beta	0.41
Rel Volume	0.04
Avg Volume	12.15M
Volume	522,604

Perf Week	-8.72%
Perf Month	-44.54%
Perf Quarter	-29.17%
Perf Half Y	-72.17%
Perf YTD	-74.21%
Perf Year	-95.69%
Perf 3Y	-94.15%
Perf 5Y	-99.75%
Perf 10Y	-99.86%
Recom	3.00
Target Price	1.00
Prev Close	0.17
Price	0.17
Change %	0.41%

Consensus

Hold

Avg. Price Target

$1.00

Implied Upside

+485.8%

Analysts6incl. previous ratings

Rating Distribution1 Buy · 5 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Dec 17, 2025	Downgrade	WWilliam Blair	Outperform → Mkt Perform
Dec 17, 2025	Downgrade	SStifel	Buy → Hold	$1	+485.8%
Dec 17, 2025	Downgrade	MMaxim Group	Buy → Hold
Dec 17, 2025	Downgrade	JJefferies	Buy → Hold	$0.90	+427.2%
Dec 07, 2023	Upgrade	JJefferies	Hold → Buy	$15	+8,687.3%
Aug 07, 2023	Upgrade	MMaxim Group	Hold → Buy	$30	+17,474.7%
Jul 22, 2022	Downgrade	WWilliam Blair	Outperform → Mkt Perform
Jul 22, 2022	Downgrade	RRobert W. Baird	Outperform → Neutral
Jul 22, 2022	Downgrade	JJefferies	Buy → Hold
May 20, 2021	Initiated	RRobert W. Baird	Outperform	$9	+5,172.4%
Feb 18, 2021	Initiated	JJefferies	Buy	$6	+3,414.9%
Jan 04, 2021	Upgrade	WWilliam Blair	Mkt Perform → Outperform
Jun 27, 2018	Initiated	MMaxim Group	Buy	$6	+3,414.9%
Feb 08, 2018	Reiterated	CChardan Capital Markets	Buy	$30 → $22	+12,788.1%
Mar 28, 2017	Initiated	MMaxim Group	Buy	$4	+2,243.3%

Oct-20-26 08:30AM	Vistagen Selects GATC Health to Apply Predictive AI Across Lead Clinical-Stage Drug Development Programs (GlobeNewswire)
Sep-25-26 10:50AM	2 Falling Stocks Call Traders Are Targeting Today (Schaeffer's Research) -7.46%
Sep-24-26 09:58AM	Vistagen Presents Fasedienol Subgroup Data in Severe Social Anxiety Disorder (InvestorsHub) -19.92%
07:00AM	Vistagen Reports Positive Findings Supporting Fasedienol's Potential in Very Severe Social Anxiety Disorder (GlobeNewswire)
Sep-22-26 08:30AM	Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder (GlobeNewswire) +7.90%
08:30AM	Loading…
Sep-10-26 08:30AM	Vistagen to Present at Psych Congress 2026 (GlobeNewswire)
Aug-14-26 08:32AM	Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update (GlobeNewswire)
Aug-06-26 08:30AM	Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder (GlobeNewswire)
Aug-04-26 03:30PM	SRX Global (SRXH) Acquires Stake in Vistagen Therapeutics (NewMediaWire) +22.45%
11:35AM	SRX Global Acquires Stake in Vistagen Therapeutics (InvestorsHub)
Jul-31-26 08:30AM	Vistagen Appoints Douglas J. Williamson to its Board of Directors (GlobeNewswire)
Jun-30-26 08:00AM	Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder (Business Wire) -70.26%
Jun-15-26 04:30PM	Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update (Business Wire) +20.42%
Jun-09-26 08:30AM	Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder (Business Wire)
May-27-26 08:30AM	Vistagen to Participate in Jefferies 2026 Global Healthcare Conference (Business Wire)
08:30AM	Loading…
May-19-26 08:30AM	Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer (Business Wire) +5.81%
May-14-26 08:30AM	Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference (Business Wire)
May-12-26 07:30AM	Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder (Business Wire) -7.72%
May-08-26 07:30AM	Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder (Business Wire)
Apr-22-26 08:30AM	Vistagen Receives FDA "Study May Proceed" Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause (Business Wire)
Mar-16-26 02:38AM	Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VTGN (PR Newswire)
Mar-12-26 03:29AM	Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VTGN (PR Newswire) +5.56%
Mar-09-26 03:35AM	Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VTGN (PR Newswire)
Mar-05-26 10:38AM	Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints (Benzinga)
Mar-04-26 09:00AM	Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 16, 2026 to Discuss Your Rights - VTGN (PR Newswire)
Mar-03-26 08:30AM	Vistagen to Participate in Upcoming Investor Conferences (Business Wire)
Feb-25-26 08:30AM	Vistagen to Participate in the 46th Annual TD Cowen Healthcare Conference (Business Wire)
Feb-13-26 12:02AM	Vistagen Therapeutics Inc (VTGN) Q3 2026 Earnings Call Highlights: Progress in Clinical Trials ... (GuruFocus.com) -7.23%
Feb-12-26 05:45PM	VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:30PM	Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update (Business Wire)
07:39AM	Loading…
Feb-11-26 07:39AM	Earnings To Watch: Vistagen Therapeutics Inc (VTGN) Reports Q3 2026 Result (GuruFocus.com)
Feb-05-26 05:19AM	Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VTGN (PR Newswire)
Feb-04-26 08:30AM	Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026 (Business Wire)
Jan-29-26 04:27AM	Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VTGN (PR Newswire) -7.60%
Jan-19-26 01:50AM	Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VTGN (PR Newswire)
Dec-17-25 08:30AM	Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder (Business Wire) -80.25%
Dec-01-25 08:30AM	Vistagen Appoints Nick Tressler as Chief Financial Officer (Business Wire) -9.59%
Nov-26-25 08:30AM	Vistagen Reports Findings on PH80's Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting (Business Wire)
Nov-14-25 12:06AM	Vistagen Therapeutics Inc (VTGN) Q2 2026 Earnings Call Highlights: Progress in Palisade 3 Trial ... (GuruFocus.com)
Nov-13-25 05:55PM	VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -6.63%
04:30PM	Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update (Business Wire)
Nov-12-25 08:45AM	XOMA Royalty (XOMA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:31AM	What To Expect From Vistagen Therapeutics Inc (VTGN) Q2 2026 Earnings (GuruFocus.com)
Nov-10-25 08:30AM	Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025 (Business Wire)
Nov-05-25 05:45PM	Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
08:30AM	Vistagen to Participate in Stifel Healthcare Conference 2025 (Business Wire)
Nov-03-25 08:30AM	Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder (Business Wire) +7.61%
Nov-02-25 05:05AM	Analysts Predict Up to 550% Rally for These 2 Strong Buy Penny Stocks (TipRanks)
Oct-30-25 08:15AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -5.30%
Oct-29-25 05:20PM	Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
08:30AM	Vistagen Appoints Paul Edick to its Board of Directors (Business Wire)
Oct-28-25 05:23AM	Arcus Biosciences (RCUS) Surges 7.5%: Is This an Indication of Further Gains? (Zacks)
Oct-16-25 08:30AM	Vistagen to Present at The Menopause Society 2025 Annual Meeting (Business Wire)
Sep-26-25 02:30PM	Janus Henderson Just Took a 13.6% Stake in Vistagen. Should You Buy VTGN Stock Now? (Barchart)
Sep-09-25 08:30AM	Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit (Business Wire)
Sep-02-25 03:51AM	Vistagen Therapeutics, Inc. (VTGN) Eyes Breakthrough with Phase 3 Social Anxiety Trial (Insider Monkey) +5.39%
Aug-08-25 09:02AM	Vistagen Therapeutics Inc (VTGN) Q1 2026 Earnings Call Highlights: Advancing Key Trials Amid ... (GuruFocus.com) +8.79%
Aug-07-25 07:20PM	VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -8.08%
04:30PM	Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update (Business Wire)
Aug-06-25 06:15PM	Exact Sciences (EXAS) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
Aug-05-25 10:00AM	Inovio Pharmaceuticals (INO) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jul-31-25 08:30AM	Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025 (Business Wire)
Jul-24-25 08:30AM	Vistagen to Present at the BTIG Virtual Biotechnology Conference (Business Wire)
Jul-15-25 08:30AM	Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership (Business Wire) -5.46%
Jul-02-25 10:03PM	Stifel Maintains Buy on Vistagen Therapeutics, Inc. (VTGN) Despite PAL-4 Delay (Insider Monkey)
Jun-25-25 08:30AM	Vistagen Appoints Elissa Cote as Chief Corporate Development Officer (Business Wire)
Jun-18-25 03:01AM	Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid ... (GuruFocus.com) -13.45%
Jun-17-25 04:30PM	Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update (Business Wire)
05:20AM	Results season slows to a dribble (MarketWatch)
04:11AM	Stock Market Today: Dow, S&P 500 and Nasdaq marked lower as Trump says to 'evacuate Tehran' with Fed decision, retail sales on tap (MarketWatch)
Jun-16-25 09:16AM	Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Report Preview: What to Look For (GuruFocus.com) +6.79%
Jun-12-25 08:30AM	Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025 (Business Wire)
Jun-02-25 08:30AM	Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year (Business Wire) -6.01%
May-28-25 08:30AM	Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York (Business Wire)
May-23-25 08:30AM	Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference (Business Wire)
May-15-25 09:15AM	Opus Genetics, Inc. (IRD) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-14-25 05:35PM	Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-13-25 05:15PM	Seer, Inc. (SEER) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-12-25 05:10PM	Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
Apr-17-25 08:30AM	Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference (Business Wire)
Mar-19-25 08:30AM	Vistagen to Present at the 2025 Anxiety and Depression Association Conference (Business Wire)
Mar-04-25 08:30AM	Vistagen to Participate in Stifel 2025 Virtual CNS Forum (Business Wire) +6.43%
Feb-20-25 08:30AM	Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference (Business Wire)
Feb-14-25 02:22AM	Vistagen Therapeutics Inc (VTGN) Q3 2025 Earnings Call Highlights: Promising Trial Results and ... (GuruFocus.com)
Feb-13-25 05:55PM	VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:30PM	Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update (Business Wire)
Feb-12-25 07:51AM	Earnings To Watch: Vistagen Therapeutics Inc (VTGN) Reports Q3 2025 Result (GuruFocus.com)
Feb-06-25 08:30AM	Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025 (Business Wire)
Feb-05-25 08:30AM	Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain (Business Wire)
Jan-15-25 05:16AM	Vistagen reports positive outcomes from Phase IIA cancer cachexia trial (Clinical Trials Arena)
Jan-14-25 08:30AM	Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia (Business Wire)
Jan-10-25 08:30AM	Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder (Business Wire)
Nov-14-24 08:30AM	Vistagen to Present at the Stifel 2024 Healthcare Conference (Business Wire)
Nov-08-24 02:31AM	Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlights: Navigating Challenges with a ... (GuruFocus.com)
Nov-07-24 07:30PM	VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:20PM	Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update (Business Wire)
Nov-06-24 07:51AM	Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Report Preview: What to Expect (GuruFocus.com)
Nov-05-24 08:30AM	Vistagen to Present at the 2024 Neuroscience Education Institute Congress (Business Wire)
Nov-01-24 08:30AM	Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024 (Business Wire)

Show Previous News

Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for depression and neurological disorders, PH15 acute treatment for improvement of cognition, PH80 acute management of vasomotor symptoms due to menopause, and PH284 acute management of Wasting syndrome (Cachexia). The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

PresidentMr. Shawn K. Singh J.D.

CFO & TreasurerMr. Nick B. Tressler M.B.A.

Chief Operating OfficerMr. Joshua S. Prince M.B.A.

J.D.Mr. Reid G. Adler Esq.

Chief Corporate Development & Strategy OfficerMs. Elissa Cote

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VTGN

Vistagen Therapeutics Inc

Upgrade your Finviz experience